Cryo-Cell InternationalCCEL
CCEL
About: Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
Employees: 86
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
43% more funds holding
Funds holding: 14 [Q3] → 20 (+6) [Q4]
33% more capital invested
Capital invested by funds: $5.74M [Q3] → $7.64M (+$1.9M) [Q4]
1.61% more ownership
Funds ownership: 11.18% [Q3] → 12.8% (+1.61%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8.50
32%
upside
Avg. target
$8.50
32%
upside
High target
$8.50
32%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Allen Klee 28% 1-year accuracy 5 / 18 met price target | 32%upside $8.50 | Buy Maintained | 4 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
1 month ago
Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2024
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for its fiscal year ended November 30, 2024. Financial Results Revenue Consolidated revenues for fiscal 2024 were $32.0 million compared to $31.3 million for fiscal 2023. The revenues for fiscal 2024 consisted of $31.6 million in processing and storage fee revenue, $68,000 in product revenue.
Neutral
Business Wire
2 months ago
Cord Blood Banking Leader Cryo-Cell Announces Regular Quarterly Cash Dividend and Pause of Strategic Initiatives
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a quarterly cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on February 14, 2025. The dividend is expected to be paid on February 28, 2025. The Board of Directors.
Neutral
Business Wire
5 months ago
Cord Blood Banking Leader Cryo-Cell Declares Initiation of Regular Quarterly Cash Dividend
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (“Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, announced today that its Board of Directors has approved the payment of a regular quarterly cash dividend at an initial rate of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024. The dividend is expected to be paid on November 29, 20.
Neutral
Business Wire
5 months ago
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2024 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2024. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2024 were $8.07 million compared to $7.87 million for the third quarter of fiscal 2023. Net Income The Company reported net income for the three months e.
Neutral
Business Wire
8 months ago
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2024 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2024. Financial Results Revenue Consolidated revenues for the second quarter of fiscal 2024 were $8.0 million compared to $7.8 million for the second quarter of fiscal 2023, a 3% increase. The revenues for the second quarter of fiscal 2024 consiste.
Neutral
Business Wire
11 months ago
Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2024 Financial Results
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world's first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 29, 2024. Financial Results Revenue The revenues for the first quarter of fiscal 2024 were $7.85 million compared to $7.82 million for the first quarter of fiscal 2023. The revenues for the first quarter of fiscal 2024 consisted of $7.81 million i.
Neutral
Business Wire
1 year ago
Cryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value
OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company” or “Cryo-Cell”), the world's first private cord blood bank to separate and store stem cells in 1992, today announced that its Board of Directors has authorized the spin-off of its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or.
Charts implemented using Lightweight Charts™